The increasing prevalence for muscle-building peptides has spawned a large grey market, posing both novel possibilities and considerable risks. These unlicensed products, often sourced from foreign laboratories, bypass established pharmaceutical processes, permitting purchase at discounted prices. However, the absence of quality control and rigorou